GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Baijin Life Science Holdings Ltd (OTCPK:MNNGF) » Definitions » Change In Payables And Accrued Expense

MNNGF (Baijin Life Science Holdings) Change In Payables And Accrued Expense : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Baijin Life Science Holdings Change In Payables And Accrued Expense?

Baijin Life Science Holdings's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2024 was $0.00 Mil. It means Baijin Life Science Holdings's Accounts Payable & Accrued Expense stayed the same from Mar. 2024 to Sep. 2024 .

Baijin Life Science Holdings's Change In Payables And Accrued Expense for the fiscal year that ended in Mar. 2024 was $0.00 Mil. It means Baijin Life Science Holdings's Accounts Payable & Accrued Expense stayed the same from Mar. 2023 to Mar. 2024 .


Baijin Life Science Holdings Change In Payables And Accrued Expense Historical Data

The historical data trend for Baijin Life Science Holdings's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baijin Life Science Holdings Change In Payables And Accrued Expense Chart

Baijin Life Science Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Baijin Life Science Holdings Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Baijin Life Science Holdings Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baijin Life Science Holdings Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Baijin Life Science Holdings's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Baijin Life Science Holdings Business Description

Traded in Other Exchanges
Address
66 Gloucester Road, Office B, 9/F Pico Tower, Wanchai, Hong Kong, HKG
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company produces health products that are affordable for the general public. The business segments of the company are Life Science segment which includes cellular technology-based services, provide including cellular drugs R&D, large molecule drugs R&D, clinical research services and R&D and sales on self-owned skincare brand, and Fine Jewelry segment that focuses on the procurement, processing, design, production and wholesale distribution of pearls and fine jewelry products.

Baijin Life Science Holdings Headlines